Analytical Data
-
Gene name
ANLN
- Application
-
Alternative Names
Scra; Scraps; Actin-Binding Protein Anillin
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NQW6
-
Expression Region
Cys712~Pro1124
-
Molecular Weight
50&35kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ANLN (anillin) is a crucial actin-binding protein that plays a significant role in the regulation of the cytoskeleton during cell division and maintaining cellular architecture. Research on ANLN has garnered interest due to its involvement in various cellular processes, including cytokinesis, cell adhesion, and migration. Abnormal expression or function of ANLN has been implicated in several pathological conditions, notably cancer, making it a potential biomarker and therapeutic target. The study of ANLN recombinant proteins allows for a deeper understanding of its structural and functional properties, enabling researchers to dissect the molecular mechanisms underlying its role in cell division and disease progression. Through recombinant DNA technology, scientists can produce ANLN in a controlled environment, facilitating the exploration of its interactions with other proteins and its effects on cellular dynamics. This research not only contributes to the fundamental understanding of cytoskeletal dynamics but also holds promise for the development of innovative strategies in cancer treatment and regenerative medicine, as modulation of ANLN activity could provide new avenues for therapeutic intervention.
